BioSpace News Archive

BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”) today announced 2022 fourth quarter and full year preliminary unaudited revenue and introduced 2023 revenue guidance.

Rejuvenate Bio, today announced new preclinical research published to the preprint server bioRxiv, that evaluates how partial reprogramming could be a potential treatment in the elderly to reverse age-associated diseases and potentially extend human lifespan.

Alloy Therapeutics, a biotechnology ecosystem company, announced its 2023 roadmap of new discovery technologies and services across a range of biologic modalities.

Guardant Health, Inc. today announced preliminary, unaudited results for the year ended December 31, 2022.

Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced preliminary (unaudited) net sales results for its fourth quarter and full year ended December 31, 2022.

Stuart Therapeutics, Inc. announces that it has expanded its drug development pipeline, adding programs in diabetic macular edema and myopia.

Myrtelle Inc. (“Myrtelle” or the “Company”), a gene therapy company focused on developing transformative treatments for neurodegenerative diseases, today announced updated initial findings of the 8 patients treated with the Company’s recombinant adeno-associated virus (rAAV) vector-based investigational gene therapy for open-label Phase 1/2 First-in-Human (FIH) clinical trial for Canavan disease (CD), a fatal genetic disorder in children.

AtriCure, Inc. announced preliminary financial results for the fourth quarter and full year 2022 and provided 2023 financial guidance.

DexCom, Inc. today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2022 to be at least $815 million, an increase of 17% over the fourth quarter of 2021 on a reported basis and 20% on an organic 1 basis.

Agiliti, Inc. today announced that Tom Leonard will retire as Agiliti CEO on March 10, 2023, and continue on as a member of the company’s Board of Directors.